Member Area

Farmavita.Net - Pharmaceutical Licensing Network

Thursday
Mar 11th
Home arrow Farmavita.Net Journal arrow Intellectual Property
Farmavita.Net - Intellectual Property
Croatia_Dugi_Otok

This section is about issues of intellectual property in pharmaceutical industry.

Contributions from members are very welcome. Every article is published with full credentials of Author. Please  Register as the member and submit your article.



Print E-mail
Intellectual Propriatery News
Written by Administrator   
Tuesday, 30 January 2007

mk

PHARMACEUTICAL PATENTS and its’ AFFECTS on GENERIC MARKETS

We  would be pleased to announce our future seminar entitled PHARMACEUTICAL PATENTS and its’ AFFECTS on GENERIC MARKETS
Read more...
 
Print E-mail
Intellectual Propriatery News
Written by Jesse Tale   
Thursday, 02 November 2006

genericsweb 

More to Veterinary Anthelmintic ProHeart® than Green Book Indicates 

Analysis of the GenericsWeb Pipeline Patent Intelligence for Wyeth’s top selling veterinary anthelmintic ProHeart® (Moxidectin) shows that generic manufacturers should be wary of relying upon the US FDA Green Book for their critical patent expiry information.

Read more...
 
Print E-mail
Intellectual Propriatery News
Written by Jesse Tale   
Wednesday, 06 September 2006

Avandia® Patents Afford Protection Against Generic Competition 

Generic pharmaceutical manufacturers should proceed with caution when developing generic versions of Avandia®, (Rosiglitazone maleate), according to experts at GenericsWeb.

Read more...
 
Print E-mail
Intellectual Propriatery News
Written by Administrator   
Saturday, 22 July 2006

Lupin loses patent suit about Ramipril in America

MUMBAI: Pharmaceutical company Lupin on Thursday said a district court in the US has ruled against the company in a patent infringement suit filed by Sanofi-Aventis and King Pharmaceuticals.

Read more...
 
Print E-mail
Intellectual Propriatery News
Written by Jesse Tale   
Wednesday, 24 May 2006

Full Story of Relpax Patent Protection Not Told by Orange Book?

Pfizer’s oral anti-migraine medicine Relpax, (Eletriptan hydrobromide) appears to have more patent protection than meets the eye.    A report by GenericsWeb has uncovered an array of patent protection in terms of molecular form, active ingredient synthesis, formulations and medical use on not only the commercial product but also on potential commercial alternatives for generic competitors.

Read more...
 
Print E-mail
Intellectual Propriatery News
Written by Jesse Tale   
Wednesday, 01 March 2006

How to Calculate Standard Patent Expiry Dates and Data Exclusivity in Key Territories

Use this handy guide to navigate the calculation of patent expiry dates in US, Canada, Germany, Spain, France, United Kingdom and Australia, and also data exclusivity in the US, Canada, Europe and Australia.

Read more...
 
Print E-mail
Intellectual Propriatery News
Written by Zdravko Mauko   
Thursday, 23 February 2006

Evergreening through Patent Strategies

One form of evergreening occurs when the originator manufacturer “stockpiles” patent protection by obtaining separate 20-year patents on multiple attributes of a single product. But many other evergreening strategies exist ...

Information provided by European Generic Association.
Read more...
 
Print E-mail
Intellectual Propriatery News
Written by Zdravko Mauko   
Monday, 02 January 2006

 Strategies for early generic launch - Atorvastatin

 

 

DubrovnikThe major constraining patent for Atorvastaitn is EP-00247633. Patentee is Warner-Lambert company. Priority date is 30 May 1986.  SPC for EP-00247633 will expire in Nov. 2011 in number of EU countries. However, in Slovenia, Czech R., Bulgaria, Hungary, Poland and Slovakia there is no national patents with link to  EP-00247633 as primary patent.

Read more...
 
Print E-mail
Intellectual Propriatery News
Written by Zdravko Mauko   
Wednesday, 21 December 2005

Strategies for successful generic launch in European Union - Sildenafil case

The experts of  Framvita.Net have made an brief analysis of  current status of intellectual property and generic products  about  sildenafil.  This  article may help you in planning of successful launch of generic sildenafil in European Union.
Read more...
 
<< Start < Prev 1 2 Next > End >>

Results 10 - 18 of 18
Advertisement
 

Featured Video

More videos ...

3D Content Cloud

Featured Partners

farmavita_research-store.gif
top-20-cancer-therapy-brand.jpg
generics-growth-strategies2.gif
sfe_eu10_150x150_v2.gif 
mddexeceu10_150x150_v1.gif
discovery2010_150x150.gif
150x150_salesonco-master.gif
pharma_omaeu10_150x150_v2.gif
risksharingnextlevel.gif 
arriello-150x150.gif 
150x150_ceepr3_master.gif 
pharmabrand2010_150x150.gif
 

Login to Farmavita.Net

membership is FREE

Follow us on:

bpe_oglas.gif




Join our LinkedIn Group

BabelFish Translator




Click Flag for Translation

Who's Online

We have 4 guests online

Farmavita.Net RSS News


Products

Click to Products

JobLine

Click here ...Post a Job for Free

Reports

Click to Reports

Events

Click to Events

CRAMS

Click to CRAMS